Navigation Links
Labopharm receives complete response letter from the U.S. FDA for novel antidepressant
Date:7/20/2009

LAVAL, QC, July 20 /PRNewswire-FirstCall/ - Labopharm Inc. (TSX: DDS; NASDAQ: DDSS) today announced it has received a complete response letter from the U.S. Food and Drug Administration (FDA) for the new drug application (NDA) submission of its novel formulation of the antidepressant trazodone.

The letter indicates Labopharm's application cannot be approved in its present form due to deficiencies following an FDA inspection of the active pharmaceutical ingredient (API) manufacturing facility, which was completed July 3, 2009. The FDA letter states: "Satisfactory resolution of these deficiencies is required before this application may be approved." No efficacy or safety issues were raised.

The API manufacturer, Angelini, has informed Labopharm that, further to the FDA's complete response letter to Labopharm, in which the FDA raises observations concerning the Drug Master File (DMF) holder in the section "Facility Inspections", Angelini can confirm that the observations raised by the FDA are not critical and that it has not been questioned about the continued supply of trazodone hydrochloride to the U.S. market. Angelini intends to address the observations raised by the FDA in an action plan that Angelini is going to submit to the FDA by July 24, 2009.

"We intend to work closely with the FDA and Angelini to resolve these issues as rapidly as possible," said James R. Howard-Tripp, President and Chief Executive Officer, Labopharm Inc. "We continue to prepare for the commercialization of our novel antidepressant and intend to launch in the U.S. market as soon as possible after we receive approval."

The Company will provide further information regarding the timing of its response to the FDA when available.

Labopharm submitted the NDA for its novel formulation of trazodone in September 2008. The NDA is based on data from five pivota
'/>"/>

SOURCE Labopharm Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. Labopharm To Present Poster On Onset Of Analgesic Effect Of Once-Daily Tramadol At Congress Of The European Society Of Regional Anaesthesia And Pain Therapy
2. Labopharm provides update on U.S. regulatory process for once-daily Tramadol
3. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
4. Labopharm appeals FDAs decision on once-daily tramadol
5. Labopharm to host conference call Friday, November 9, 2007 at 8:30 a.m. (ET)
6. Labopharm to present at CIBC World Markets 18th Annual Healthcare Conference
7. Labopharm Reports Results for Third Quarter Fiscal 2007
8. Labopharm receives FDA response to appeal of Approvable Letter for once-daily tramadol
9. Labopharm enters into licensing and distribution agreement for once-daily tramadol in Australia with iNova
10. Canadian Marketing and Sales Effort for Labopharms Once-Daily Tramadol Product to Expand Significantly
11. Labopharm Reports Positive Results for Phase III Study on Once-daily Trazodone
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2014)... presence of chronic inflammation in benign prostate tissue ... and this association was found even in those ... a study published in Cancer Epidemiology, Biomarkers ... Association for Cancer Research. , An analysis of ... the placebo arm of the Prostate Cancer Prevention ...
(Date:4/17/2014)... popular vaccine brands for children may not be the ... cost factors when choosing vaccines, driving the market toward ... a new study by University of Illinois researchers. , ... by numerous factors," says Sheldon H. Jacobson, a co-author ... and of mathematics at the U. of I. "In ...
(Date:4/17/2014)... Colo. (April 17, 2014) Two recent papers ... researcher and colleagues may help scientists develop treatments ... Yellow fever, Japanese encephalitis and other disease-causing flaviviruses. ... biochemistry and molecular genetics at the School of ... Howard Hughes Medical Institute, and colleagues recently published ...
(Date:4/17/2014)... Rochelle, NY, April 17, 2014U.S. military personnel who ... plus impact" concussive traumatic brain injury (TBI) were ... evacuated for other medical reasons. Differences in measures ... depression 6-12 months after injury are reported in ... a peer-reviewed journal from Mary Ann Liebert, Inc., ...
(Date:4/17/2014)... CHICAGO, IL, April 17, 2014-- Colic affects about one ... accounts for numerous pediatric visits during the first several ... of colic symptoms was showing promise; however, the April ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics ... probiotic L reuteri for infant colic ...
Breaking Medicine News(10 mins):Health News:Chronic inflammation may be linked to aggressive prostate cancer 2Health News:Chronic inflammation may be linked to aggressive prostate cancer 3Health News:Study recalculates costs of combination vaccines 2Health News:CU researchers discover target for treating dengue fever 2Health News:Long-term effects of battle-related 'blast plus impact' concussive TBI in US military 2Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2
... health committee is all set to tighten the screws ... days of public hearing starting on Jan 23, is ... will make submissions before the committee. ,Under ... the sponsorship of sports and other popular events by ...
... way that primary care is organized, delivered, financed, and ... were released today by the American College of Physicians ... the Nation's Health Care. ,The U.S. health ... medicine, the ACP reported in its January 2006 State ...
... viral culture system, which makes way for a better ... replication of virus// (isolated from patient) in non-transformed hepatocytes. ... in transformed cell lines. ,The study report ... transfected and serum-infected cultured human fetal hepatocytes,’ appears in ...
... been accomplished by people who have kept on trying when there ... ,A groundbreaking venture has been ... cancer-treatment, are mass-produced in the egg white of a certain breed ... is one of the leading causes of death in the world. ...
... known as microchimerism has been known for some years, that ... pregnancy, and that these may live on for many// years, ... still unclear as to whether the presence of such cells ... team has looked for maternal cells in children with type ...
... findings that point to yet another benefit of statins; improving ... prescribed for heart patients. They work by lowering the levels ... in arteries. ,The drugs have also been shown ... of heart disease from having a heart attack or stroke. ...
Cached Medicine News:Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 2Health News:Comprehensive Reforms to Move Toward Patient-Centered Care 3Health News:A Breakthrough in the Study of Hepatitis C 2Health News:'Hen Factories' To Synthesize Cancer Drugs 2Health News:Stem Cells Passed From Mother to Child Live On and Make Insulin 2Health News:Statins Aid Survival in Lung Patients, Say Experts 2
(Date:1/15/2014)... Most osteoporosis patients want a choice in the ... sponsored by Mission Pharmacal Company. The survey, conducted by ... support community, revealed that 74 percent of osteoporosis patients ... form other than a pill or a tablet. ...
(Date:1/15/2014)... N.J. , Jan. 15, 2014  Celsion Corporation (the "Company") ... has received commitments from institutional investors to purchase an ... stock in an at-the-market registered direct offering, led by ... entered into definitive purchase agreements with these investors pursuant ...
(Date:1/15/2014)... 15, 2014  Manufacturers, suppliers and distributors of innovative ... protect their most important business assets, intellectual property ... Because of the highly-competitive nature of ... of the most litigious industry sectors of cases ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... Conn., March 16, 2011 Amarin Corporation plc (Nasdaq: ... on cardiovascular disease, today reported financial results for the ... The Company also provided an update on its progress ... product candidate, AMR101 for the treatment of elevated triglyceride ...
... announces that a new market research report is available ... Industry http://www.reportlinker.com/p098391/Global-Breast-Pumps-Industry.html ... in Thousands of Units by the following Product Segments: ... provides separate comprehensive analytics for the US, Canada, Europe, ...
Cached Medicine Technology:Amarin Reports Year-End and Q4 2010 Results 2Amarin Reports Year-End and Q4 2010 Results 3Amarin Reports Year-End and Q4 2010 Results 4Amarin Reports Year-End and Q4 2010 Results 5Amarin Reports Year-End and Q4 2010 Results 6Amarin Reports Year-End and Q4 2010 Results 7Amarin Reports Year-End and Q4 2010 Results 8Amarin Reports Year-End and Q4 2010 Results 9Global Breast Pumps Industry 2Global Breast Pumps Industry 3Global Breast Pumps Industry 4Global Breast Pumps Industry 5Global Breast Pumps Industry 6Global Breast Pumps Industry 7Global Breast Pumps Industry 8Global Breast Pumps Industry 9Global Breast Pumps Industry 10
Implantable medical grade silicone end cap for insulation and sealing protection of 5 mm or 3.2 mm connectors....
... Medtronic InSync ICD cardiac resynchronization and ICD ... seconds (BOL). The unit's RV only sensing ... RV and LV depolarizations, eliminating this cause ... RV to LV separation for optimized hemodynamics. ...
... The Guidant Contak Renewal 3 ... ventricular tachyarrhythmia therapy and cardiac ... right ventricular (RV) and left ... Designed to reduce irregular ventricular ...
... The RapidLoc Meniscal Repair ... system that offers several advantages ... suture repair techniques and current ... is quick, simple, reproducible, reliable, ...
Medicine Products: